X4 Pharma has shown that cutting back and focusing on a lead asset can work but mavorixafor’s first-in-class status and efficacy profile is not common.
X4 Pharmaceuticals was one of the legions of pre-commercial biopharma companies which slashed its headcount and budgets last year, but now the firm looks on track for its first ever drug approval.
Its lead candidate is mavorixafor, a treatment for WHIM (warts, hypogammaglobulinemia, infections and myelokathexis) syndrome, a rare immunodeficiency disease, and...
Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.
Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
